Inspira Technologies Oxy BHN (IINN) AI Stock Analysis

• Market Cap: $17.14M
• Dividend Yield: N/A
• Average Volume (3M): 316.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.51
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 65
• Industry: Medical - Devices
• EPS (TTM): -0.60
• Shares Outstanding: 25,619,276
• 10 Day Avg. Volume: 252,457
• 30 Day Avg. Volume: 316,737
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Inspira Technologies Oxy BHN is currently facing significant financial and operational challenges. The lack of revenue generation and continued losses are major concerns. Technical analysis reflects a bearish outlook with downward momentum and weak price trends. The valuation does not provide enough incentive for investment given the underlying risks.

Inspira Technologies Oxy BHN Business Overview & Revenue Model

Company Description

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.

How the Company Makes Money

Inspira Technologies Oxy BHN generates revenue primarily through the sale and distribution of its proprietary medical devices, particularly the ART system. The company targets hospitals and healthcare facilities as its primary customers, offering them advanced respiratory care solutions to enhance patient treatment. Revenue is also derived from service agreements and maintenance contracts associated with their devices. Additionally, Inspira Technologies may engage in strategic partnerships with healthcare providers and distributors to expand its market reach and enhance its product offerings, contributing to its overall earnings.

Inspira Technologies Oxy BHN Financial Statement Overview

Summary

Inspira Technologies Oxy BHN shows severe financial challenges, with no revenue growth and persistent losses. The negative margins and operational inefficiencies indicate distress. The balance sheet shows some improvement in debt-to-equity but remains unstable, and the negative cash flows highlight liquidity issues.

Income Statement

The company has consistently reported no revenue over the years, indicating significant challenges in sales or market penetration. The gross profit margin remains negative, reflecting costs exceeding revenues. High negative net profit margins and continued EBIT/EBITDA losses suggest ongoing operational inefficiencies and financial distress.

Balance Sheet

The debt-to-equity ratio is improving but remains concerning with equity volatility over the years. The equity ratio is declining, indicating a decrease in asset financing through equity. The presence of net debt reflects improved cash management, but overall stability remains weak due to fluctuating equity levels.

Cash Flow

Free cash flow is consistently negative, highlighting liquidity challenges. The operating cash flow to net income ratio indicates cash outflows exceeding net losses, further emphasizing financial strain. Despite some positive financing cash flows, the overall cash flow position remains precarious, affecting operational sustainability.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	-4.68M	0.00	0.00	0.00
	Gross Profit
-406.00K	-5.04M	-218.00K	-203.00K	-76.00K
	EBIT
-12.13M	-14.77M	-13.43M	-6.27M	-1.27M
	EBITDA
-10.87M	-14.68M	-16.72M	-6.96M	-4.49M
	Net Income Common Stockholders
-11.29M	-4.00M	-16.96M	-7.23M	-4.58M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.36M	13.90M	23.75M	496.00K	96.00K
	Total Assets
9.31M	16.01M	25.87M	987.00K	374.00K
	Total Debt
878.00K	1.46M	1.48M	1.92M	4.84M
	Net Debt
-4.16M	-5.33M	-22.27M	1.42M	4.74M
	Total Liabilities
3.57M	3.19M	5.52M	2.69M	5.01M
	Stockholders Equity
5.74M	12.82M	20.35M	-1.70M	-4.64M
Cash Flow		Free Cash Flow
-9.96M	-7.68M	-8.05M	-1.90M	-1.14M
	Operating Cash Flow
-9.76M	-7.38M	-7.88M	-1.88M	-1.11M
	Investing Cash Flow
4.59M	-7.25M	-246.00K	-26.00K	-71.00K
	Financing Cash Flow
3.45M	-399.00K	30.42M	2.29M	1.27M

Inspira Technologies Oxy BHN Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IINN, the sentiment is Negative. The current price of 0.64 is below the 20-day moving average (MA) of 0.75, below the 50-day MA of 0.85, and below the 200-day MA of 1.13, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 32.19 is Neutral, neither overbought nor oversold. The STOCH value of 13.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IINN.

Inspira Technologies Oxy BHN Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INSP	69 Neutral	$4.74B	91.13	8.48%	―	28.49%	―
GMED	69 Neutral	$11.71B	98.59	2.52%	―	60.62%	-35.88%
ECOR	54 Neutral	$48.12M	―	-158.63%	―	57.09%	52.18%
LUNG	51 Neutral	$267.83M	―	-55.25%	―	22.01%	10.02%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
NVCR	43 Neutral	$1.96B	―	-46.67%	―	18.82%	19.76%
IINN	27 Underperform	$17.14M	―	-196.69%	―	―	―